Aptevo Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 14, 2025
APVO$1.08-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(in thousands)
| For the Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating Activities | ||
| Net loss | $(24,130) | $(17,411) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 1,069 | 2,193 |
| Depreciation and amortization | 352 | 567 |
| Non-cash interest expense and other | — | 10 |
| Changes in operating assets and liabilities: | ||
| Royalty receivable | — | 2,500 |
| Prepaid expenses and other current assets | 217 | 153 |
| Operating lease right-of-use asset | 492 | 422 |
| Accounts payable, accrued compensation and other liabilities | (1,017) | 518 |
| Long-term operating lease liability | (768) | (682) |
| Net cash used in operating activities | (23,785) | (11,730) |
| Investing Activities | ||
| Net cash from investing activities | — | — |
| Financing Activities | ||
| Payments of long-term debt, including fees | — | (3,467) |
| Value of equity awards withheld for tax liability | (1) | (10) |
| Proceeds from exercise of common warrants, net of issuance costs | 5,563 | 3,047 |
| Proceeds from issuance of common stock, net of issuance costs | 10,036 | 6,428 |
| Payments in lieu of fractional shares | (3) | — |
| Net cash provided by financing activities | 15,595 | 5,998 |
| Decrease in cash and cash equivalents | (8,190) | (5,732) |
| Cash and cash equivalents at beginning of period | 16,904 | 22,636 |
| Cash and cash equivalents at end of period | $8,714 | $16,904 |
| Supplemental Cash Flow Information | ||
| Warrant modification - incremental value | $472 | $2,080 |
| Fair value of December 2024 inducement transaction common warrants | $7,331 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.